Please login to the form below

Not currently logged in
Email:
Password:

ImmuneXcite boosts senior leadership

Eric Furfine, Ann DeWitt, Jim Geraghty and John Edwards join the firm

ImmuneXcite Eric FurfineImmuneXcite, a US biopharmaceutical firm, has made five appointments to its senior leadership team, four of which are new additions to its board of directors.

Eric Furfine (pictured right) has been appointed as chief scientific officer, acting chief executive officer and a member of the board.

He brings over 25 years of drug industry experience to the leadership team, specialising in driving developments in infectious disease, inflammation and oncology therapeutic areas.

Before joining ImmuneXcite, Furfine served as president of research and development at Eleven Biotherapeutics from 2011 to 2013 and was the senior vice president for research and preclinical development at Adnexus Therapeutics - a Bristol-Myers Squibb research and development company - for four years prior.

Furfine said: “Being part of a company that is leading what we expect to be the next major wave in immune-oncology is an exciting proposition.

“I look forward to working with the ImmuneXcite team to build on a number of years of excellent science.”

Ann DeWitt, Jim Geraghty and John Edwards also join the ImmuneXcite board, with Edwards serving as executive chairman.

Edwards is currently executive chairman at F-star, having previously served as its chief executive officer, and brings over 30 years of biotechnology expertise from Adnexus Therapeutics, Genetics Institute/Wyeth and Genzyme.

DeWitt is senior director of investments at Sanofi-Genzyme BioVentures and brings business leadership experience from Springboard Enterprises, Permeon Biologics and Flagship Ventures.

Geraghty has 30 years of strategic and leadership experience and is currently an entrepreneur-in-residence at Third Rock Ventures, a biotech venture and company-formation fund. He is chairman of the board of Idera Pharmaceuticals and Juniper Pharmaceuticals and has previously worked at Sanofi-Aventis and Genzyme.

Finally, ImmuneXcite's scientific co-founder Ifat Rubin-Bejerano has been named as head of research.

The inventor of the company's technology platform, Rubin-Bejerano also brings 15 years of research experience to the role from Whitehead Institute where she was most recently a senior researcher.

Edwards said: “It is a privilege to collaborate with such an experienced group of colleagues in a thrilling area of drug development with the potential to make a significant shift in the treatment of cancer.”

4th April 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics